Clinical Trial Update: Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-Comer Patient Cohort With Coronary Artery Disease - the Cruz Senior Study

View source ↗

Summary

A post-market registry assessed safety and efficacy of the SUPRAFLEX CRUZ sirolimus-eluting coronary stent system in octogenarian and nonagenarian patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• SUPRAFLEX CRUZ Sirolimus Eluting Coronary Stent System (sirolimus-eluting coronary stent)

Snippet

Sponsor: IHF GmbH - Institut für Herzinfarktforschung | Conditions: Coronary Disease | Status: COMPLETED